Evidence map›Paper›PMID 39363330›Full record

ReviewActa neuropathologica communications2024

Hyperspectral retinal imaging in Alzheimer's disease and age-related macular degeneration: a review.

Xiaoxi Du, Jongchan Park, Ruixuan Zhao, R Theodore Smith, Yosef Koronyo, Maya Koronyo-Hamaoui, Liang Gao

Abstract readReview
In one paragraph

Review in Acta neuropathologica communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Snapshot hyperspectral fundus imaging system using a microlens array.medRxiv : the preprint server for health sciences · 2025
    Article
  9. Review
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoxi Du *Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
Jongchan Park *Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
Ruixuan ZhaoDepartment of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA.
R Theodore SmithOphthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA.
Yosef KoronyoDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Maya Koronyo-HamaouiDepartment of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Liang GaoDepartment of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA. gaol@ucla.edu.

Funding

Alzheimer's Disease Hallmark Pathology and Associated Inflammation in the RetinaR01AG055865 · NIA · CEDARS-SINAI MEDICAL CENTER · PI Maya Koronyo-Hamaoui · 2018 to 2026
$4.9M
Ultrafast BioimagingR35GM128761 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Liang Gao · 2018 to 2026
$3.2M
Retinal Imaging of Alzheimer's Disease PathologyR01AG056478 · NIA · CEDARS-SINAI MEDICAL CENTER · PI KORONYO-HAMAOUI, MAYA · 2017 to 2021
$2.5M
Kilohertz 3D Optical Mapping of Atrial Fibrillation in Beating Zebrafish HeartsR01HL165318 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GAO, LIANG, HSIAI, TZUNG K · 2022 to 2025
$2.2M
A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)R01EY029397 · NEI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI BOPPART, STEPHEN A, GAO, LIANG · 2019 to 2023
$1.9M
Kilohertz volumetric imaging of neuronal action potentials in awake behaving miceRF1NS128488 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GAO, LIANG, GOLSHANI, PEYMAN · 2022 to 2022
$1.6M
Kilohertz 3D voltage imaging using near-infrared confocal squeezed light field microscopyR01NS142690 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Liang Gao · 2025 to 2026
$1.1M
NEI NIH HHS R01 EY029397NEI NIH HHS R01EY029397NHLBI NIH HHS R01 HL165318NHLBI NIH HHS R01HL165318NIA NIH HHS R01 AG055865NIA NIH HHS R01 AG056478NIA NIH HHS R01AG056478NIGMS NIH HHS R35 GM128761NINDS NIH HHS R01 NS142690NINDS NIH HHS RF1 NS128488NINDS NIH HHS RF1NS128488
6 · The paper itself

Abstract

While Alzheimer's disease and other neurodegenerative diseases have traditionally been viewed as brain disorders, there is growing evidence indicating their manifestation in the eyes as well. The retina, being a developmental extension of the brain, represents the only part of the central nervous system that can be noninvasively imaged at a high spatial resolution. The discovery of the specific pathological hallmarks of Alzheimer's disease in the retina of patients holds great promise for disease diagnosis and monitoring, particularly in the early stages where disease progression can potentially be slowed. Among various retinal imaging methods, hyperspectral imaging has garnered significant attention in this field. It offers a label-free approach to detect disease biomarkers, making it especially valuable for large-scale population screening efforts. In this review, we discuss recent advances in the field and outline the current bottlenecks and enabling technologies that could propel this field toward clinical translation.

Indexed as

Alzheimer DiseaseMacular DegenerationRetinaAnimalsHumansHyperspectral ImagingAge-related macular degenerationAlzheimer’s diseaseHyperspectral imagingNeurodegenerative diseaseRetinal imaging

Identifiers

PMID39363330
PMCPMC11448307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.